An exploratory study on the establishment and evaluation of individualized HAART

An exploratory study on the establishment and evaluation of individualized HAART - Keio-HAART study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006133

Enrollment

300

Registered

2011-08-10

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV-positive patients 20 years or older Written informed consent obtained from the subject.

Exclusion criteria

Exclusion criteria: Patients during pregnancy or lactation Patients who we consider inappropriate

Design outcomes

Primary

Measure	Time frame
1. HIV tropism 2. relationship between HIV tropism and patient backgrounds A Patient backgrounds(age,sex,date of diagnosis, HIV-RNA, CD4 counts at diagnosis, lowest CD4 counts, treatment history, regimen/dose/treatment term, drugs, AIDS history) B drug concentrations in blood C drug concentrations in hair and saliva D HIV-RNA in saliva E drug susceptibility F HIV-RNA and CD4 counts at the time of HIV tropism testing G metabolic marker such as bone density at the time of HIV tropism testing	—

Measure

Time frame

1. HIV tropism 2. relationship between HIV tropism and patient backgrounds A Patient backgrounds(age,sex,date of diagnosis, HIV-RNA, CD4 counts at diagnosis, lowest CD4 counts, treatment history, regimen/dose/treatment term, drugs, AIDS history) B drug concentrations in blood C drug concentrations in hair and saliva D HIV-RNA in saliva E drug susceptibility F HIV-RNA and CD4 counts at the time of HIV tropism testing G metabolic marker such as bone density at the time of HIV tropism testing

—

Secondary

Measure	Time frame
Time course of above factors	—

Countries

Japan

Contacts

Public ContactNaoki Hasegawa

Keio University School of Medicine Centor for Infectious Disease and Infection Control

03-3353-1211

Outcome results